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Introduction
Aspirin is themost commonly utilized antiplatelet agent and
it exerts its effects by inhibiting thromboxane A2 production
via irreversible cyclooxygenase-1 (COX-1) blockade.1 How-
ever, a considerable number of patients with atherosclerotic
diseasemanifestations treatedwith aspirin persist with high
levels of platelet reactivity, also known as high on-aspirin
residual platelet reactivity (HARPR), a phenomenon asso-
ciated with an increased risk of ischaemic events.2–6
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Abstract Chronic treatment with aspirin in healthy volunteers (HVs) is associated with recovery of
adenosine diphosphate (ADP)-induced platelet activation. The purinergic P2Y1 receptor
exerts its effects via a Gq-protein, which is the same biochemical pathway activated by
thromboxane-A2 receptor. We hypothesized that recovery of ADP-induced platelet activa-
tion could be attributed to increased P2Y1 expression induced by chronic aspirin exposure.
We performed a multi-phase investigation which embraced both in vitro and in vivo
experiments conducted in (1) human megakaryoblastic DAMI cells, (2) human megakar-
yocytic progenitor cell cultures, (3) platelets obtained fromHVs treated with aspirin and (4)
platelets obtained fromaspirin-treatedpatients. DAMI cells treatedwithaspirinorWY14643
(PPARα agonist) had a significant up-regulation of P2Y1 mRNA, which was shown to be a
PPARα-dependentprocess. Inhumanmegakaryocyticprogenitors, in thepresenceof aspirin
or WY14643, P2Y1 mRNA expression was higher than in mock culture. P2Y1 expression
increased in platelets obtained fromHVs treatedwith aspirin for 8weeks. Platelets obtained
from patients who were on aspirin for more than 2 months had increased P2Y1 expression
and ADP-induced aggregation compared with patients on aspirin treatment for less than a
month. Overall, our results suggest that aspirin induces genomic changes in megakaryo-
cytes leading to P2Y1 up-regulation and that PPARα is the nuclear receptor involved in this
regulation. Since P2Y1 is coupled to the same Gq-protein of thromboxane-A2 receptor,
platelet adaptation in response to pharmacological inhibition seems not to be receptor
specific, but may involve other receptors with the same biochemical pathway.
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Cellular Haemostasis and Platelets
Studies have shown that chronic use of aspirin can enhance
expression of several proteins that can potentially affect
cardiovascular outcomes.7,8 In particular, it has been demon-
strated that aspirin modulates miRNAs9,10 and gene expres-
sion, such as the nuclear receptor PPARαmodulation resulting
in an increase in platelet MRP4.11 Importantly, increased
expression of MRP4 in platelets contributes to HARPR.12–14
Overall, thesefindings suggest a ‘platelet adaptation’process in
response to chronic treatment with aspirin, which originates
inmegakaryocytes and leads to recoveryof platelet function.15
Adenosine diphosphate (ADP) is one of the major platelet
agonists and plays a key role in shape changes and platelet
aggregation via purinergic receptors.16,17 After initial reduc-
tion in platelet reactivity, treatment with aspirin in healthy
volunteers (HVs) has shown to be associated with recovery of
ADP-induced platelet activation.18 Importantly, the purinergic
P2Y1 receptor, which triggers calcium mobilization resulting
in platelet shape change and weak, transient aggregation in
response to ADP, exerts its effects via a Gq protein, which is the
same biochemical pathway activated by the thromboxane A2
receptor.17,19,20 Therefore, we hypothesized that recovery of
ADP-induced platelet activation could be attributed to
increased P2Y1 expression induced by chronic exposure to
aspirin therapy. To support our study hypothesis we per-
formed a comprehensive multi-phase investigation, which
embraced both in vitro and in vivo experiments.
Methods
Experimental Design
The experimental design of our investigationwas performed
in several phases as outlined below.
• To define if aspirin can induce P2Y1 up-regulation through
a direct action on megakaryocyte gene, we studied the in
vitro effects of aspirin on P2Y1 expression in a human
megakaryoblastic cell line (DAMI) and in human mega-
karyocytic cells (MKs).
• To determinewhether P2Y1 expression is a PPARα-depen-
dent process, we assessed DAMI cells transfected with
PPARα-specific siRNA (PPAR-si).
• To explore the specificity of in vivo aspirin treatment to
induce P2Y1 overexpression, we studied P2Y1 expression
in platelets obtained from HVs before and after aspirin
treatment (100 mg daily).
• To explore whether time of exposure to chronic aspirin
treatment influences P2Y1 expression, we studied plate-
lets obtained from patients that were on aspirin therapy
for different durations (<1 month vs. >2 months).
• To define whether time of exposure to chronic aspirin
treatment influences platelet reactivity, we studied levels
of ADP-induced platelet aggregation according to time of
exposure (<1 month vs. >2 months) to aspirin therapy in
patients on chronic aspirin treatment.
Study Population
Subjects enrolled in this investigation were those already
reported in a previous publication from our group.12 All
subjects provided their written informed consent to parti-
cipate in the study. In particular, two population cohorts
were included.
• 80 non-medicated HVs of Caucasian race volunteers (age
42  16 years; male 60%); of these 10 participated in the
pharmacodynamics investigation following aspirin
(100 mg daily) exposure for 8 weeks with assessments
conducted at various time points: after 1 day (T1), 3weeks
(T3), 5 weeks (T5) and 8 weeks (T8) of treatment. Com-
pliance was assessed by pill count.
• 110 patients with a history of coronary heart disease or
with one or more risk factors for atherothrombosis on
aspirin treatment (100 mg daily) as part of their standard
of care; 70 patients were on aspirin therapy for at least
2 months (aspirin-treated patients [ASA] > 2 months)
and 40 treated with aspirin for less than 1 month (ASA
< 1 month), a small cohort of those previously ana-
lyzed.12 Compliance was assessed by interview and con-
firmed by arachidonic acid-induced platelet aggregation
(0.75 mM) <10% (in 93% of patients arachidonic acid-
induced platelet aggregation was absent, while in the
remaining 7% it was 9.8  2.9%). Demographic and clin-
ical characteristics of the patient cohort are reported
in ►Table 1.
DAMI Cultures
The humanmegakaryoblastic cell line DAMI was maintained
in RPMI supplemented with 10% heat-inactivated foetal
bovine serum, 20 mM L-glutamine, 100 units/mL of peni-
cillin G sodium and 100 µg/mL streptomycin sulphate in a
humidified atmosphere containing 5% CO2 at 37°C.21 The
DAMI cell line was kept under control and its membrane
phenotypewas periodicallymonitored by fluorescence-acti-
vated cell sorting analysis.11 Cells were treated with either
aspirin (10, 50 or 100 μM) or PPARα agonist (WY14643) (1
μM; SIGMA Chemicals Company, St. Louis, Missouri, United
States)22 for 48 and 96 hours. In amockculture, an equivalent
amount of DMSO, present in aspirin and WY14643 suspen-
sion, was added. At the end of treatment, cells were pro-
cessed for RNA and protein extraction.11
RNA Interference
Double-stranded small interfering RNA (siRNA) targeting
human PPARα and a control non-specific siRNA (CTR-si;
Santa Cruz Biotechnology, Santa Cruz, California, United
States) were transfected by means of the Lipofectamine
RNAiMAX Reagent (Invitrogen, San Diego, California, United
States).11
Purification of Human Haematopoietic Progenitor Cell
and MK Cultures
CD34þ haematopoietic progenitor cells (HPCs), obtained
from healthy donor peripheral blood after informed consent,
were purified by MACS columns (Milteny) according to the
manufacturer’s instructions.
HPCs (1  105 cells/mL) were grown in foetal calf serum
free (FCS) unilineageMK liquid culture,23,24 in the presence
of saturating doses of thrombopoietin for 12 days. Either
aspirin (50 µM) or WY14643 (1µM) were added at day 6 of
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differentiativeMK culture (when themajority of the cells are
MK precursors) for 4 days.11 MKs were collected during the
terminal days of differentiation to evaluate P2Y1 mRNA
expression.
Platelet Preparation and Isolation
Platelet-rich plasma (PRP) and plasma-free platelets were
obtained as previously reported.25 Platelet pellet was re-
suspended with Tyrode’s buffer (containing 134 mM NaCl,
12 mM NaHCO3, 2.9 mM KCl, 5 mM glucose, 20 mM HEPES,
1 mMMgCl2, 0.34 mMNa2HPO4, pH 7.3) with the addition of
EDTA (5 mM), and then filtered on a 5-μm adaptable filter to
remove contamination of white blood cell.26 After centrifu-
gation at 800 g for 15 minutes, a platelet pellet without
contaminants was obtained, which was stored at 80°C. To
show that leukocyte contamination was not significantly
detectable, we analysed the mature transcript for CXCL8, a
leukocyte-specific gene product.27
Protein Extraction and Western Blot
To analyse P2Y1 protein expression, cells were washed twice
with cold PBS, collected and centrifuged at 400 g for 10 min-
utes. Platelets were washed twice with platelet-washing buf-
fer, collectedandcentrifugedat 7,000 g for 3minutes. Platelets
and cell pellets were then re-suspended in a sample buffer
containing phosphatase and protease inhibitors. Platelet and
cell lysates were incubated on ice for 30 minutes and centri-
fuged at 13,000 rpm for 30minutes, the supernatant was then
collected. Protein extracts (30 μg) were incubated at 100°C for
10minutes and separated by SDS–polyacrylamide gel electro-
phoresis on a 10% bis–tris polyacrylamide gel according to
manufacturer’s instructions (Bio Rad, California, United
States), blotted onto PVDFmembrane (GE Healthcare, Milano,
Italy) and probedwith rabbit polyclonal anti-P2Y1 (Santa Cruz
Biotechnology, Santa Cruz, California, United States) and
mouse anti-actin (Santa Cruz Biotechnology, Santa Cruz, Cali-
fornia, United States)monoclonal antibodies. Immunoreactive
bands were visualized by enhanced chemiluminescence (Per-
kinElmer,Waltham,Massachusetts, United States). The densi-
tometric analysis was performed with the National Institutes
of Health ImageG analyzer program.
RNA Preparation and Real-Time Quantitative
Polymerase Chain Reaction Analysis
TotalRNA fromhumancell lines,MKs andhumanplateletswas
extracted using TRIzol reagent (Invitrogen, San Diego, Califor-
nia, United States). For mRNA detection 1 µg of total RNAwas
transcribed using the GeneAmp Gold RNA PCR Reagent Kit
pAW109 (Applied Biosystems, Warrington, United Kingdom)
according to the manufacturer’s suggestion. The analysis of
gene expression was performed with used quantitative real-
time polymerase chain reaction (Q-RT-PCR) using TaqMan
Master Mix and TaqMan Assay reagents (Applied Biosystems,
Warrington, United Kingdom), as previously described.28
Changes in P2Y1, CXCL8 and ACTIN mRNA amounts were
quantified by using the ΔΔCt method for relative quantization
Table 1 Baseline demographics of the study population on chronic aspirin therapy according to time of exposure to treatment
Characteristics ASA < 1 month
(N ¼ 40)
ASA > 2 months
(N ¼ 70)
p-Value
Age (mean  SD, years) 64  13 69  12 0.56
Males, n (%) 16 (40) 33 (47) 0.46
Clinical conditions, n (%)
Hypertension 11 (27) 31 (45) 0.08
Hypercholesterolaemia 9 (22) 21 (30) 0.39
Smoke 3 (7) 6 (8) 0.84
Previous MI 1 (2) 2 (3) 0.91
Previous stroke 11 (28) 16 (23) 0.58
Previous TIA 8 (19) 15 (21) 0.85
Medications, n (%)
Beta-blocking agents 7 (17) 20 (29) 0.19
Calcium antagonist 8 (20) 13 (19) 0.85
ACE-I 6 (15) 19 (27) 0.14
ARBs 8 (20) 14 (20) >0.9
Nitrates 3 (8) 8 (11) 0.5
Statin 11 (28) 19 (27) 0.96
Diuretics 3 (8) 9 (13) 0.68
Insulin/metformin 2 (5) 5 (7) 0.65
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; ASA, aspirin-treated patients; MI, myocardial
infarction; SD, standard deviation; TIA, transient ischaemic attack.
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of gene expression using SDS software version 2.3 (Applied
Biosystems, Warrington, United Kingdom).
Platelet Aggregation
Platelet aggregation was evaluated in PRP in a four-channel
aggregometer (AggRam, Helena Laboratories, Beaumont,
Texas,UnitedStates) according toTemperilli et al.29The results
are reported as the percentage of aggregation observed after
4 minutes of stimulation (%PA) in response to ADP (2 μM) and
primarymaximal platelet aggregation in response to ADP (0.8
μM) (Helena Laboratories, Beaumont, Texas, United States).
Statistical Analysis
Categorical variables are expressed as frequencies and per-
centages. Continuous variables were analysed for normal
distribution with z-test. Continuous variables following a
normal distribution are expressed as mean  standard
deviation. Comparisons between normally distributed con-
tinuous variables were performed using Student’s t-test for
paired data and by one-way ANOVA test and Bonferroni post-
hoc test for in vitro and in vivo experiments, as appropriate.
Variables not following a normal distribution are illu-
strated as a BOX plot graph, which shows the distribution
around the median of the populations. Comparisons for data
not normally distributed were evaluated by Wilcoxon test.
Results were considered statistically significant if a p-
value of less than 0.05 was reached. Statistical analysis was
performed using KaleidaGraph software 3.6 (Synergy Soft-
ware, Reading, Pennsylvania, United States).
Results
P2Y1 Expression in Aspirin-Treated DAMI Cells
The effect of aspirin on P2Y1 expression was first investigated
in in vitro experiments in a humanmegakaryoblastic cell line
(DAMI). To verify whether aspirin modulates P2Y1 expression
levels, DAMI cells were treated with aspirin (50 μM) or with
the selective PPARα agonist,WY14643,which both induced an
enhancement of P2Y1 mRNA levels compared with mock
culture, after 48 hours of treatment (►Fig. 1A). The effect of
aspirin on P2Y1-mRNAexpressionwas also evaluated inDAMI
cells grown in the presence of 10 μM of aspirin showing that
P2Y1-mRNA expression levels were similar to untreated cul-
ture until 48 hours, while at 96 hours there was an increase
which reached similar levels to those observed in cells treated
with50μMofaspirin for 48hours. Thismeans that theamount
of aspirin equivalent to that found in plasma after 100mg/day
aspirin can induce P2Y1 up-regulation (►Fig. 1A).
Western blot analysis also revealed an increase of P2Y1
protein expression in cells treated with either aspirin or
WY14643 (►Fig. 1B). Densitometry analysis showed a sta-
tistically significant higher induction of P2Y1 protein expres-
sion, which is enhanced by more than 60% compared with
untreated cells (►Fig. 1C). To confirm the involvement of
PPARα on P2Y1 up-regulation, DAMI cells were transfected
with PPAR-si. Cells transfected with PPAR-si showed a non-
significant increase of P2Y1 mRNA expression after aspirin
andWY14643 treatment, while cells transfectedwith CTR-si
showed the same aspirin- andWY14643-induced expression
changes of untransfected cells (►Fig. 1D). Overall, these data
strongly support the hypothesis that aspirin exerts a PPARα-
mediated activity on P2Y1 expression.
P2Y1 Expression in Aspirin-Treated Human
Megakaryocytic Progenitor Cell Cultures
The analysis of P2Y1 expression in DAMI cells suggested that
aspirin could also affect its expression in human MKs. Thus,
to corroborate our findings we analysed the effects of aspirin
on P2Y1 expression in differentiating human MK progenitor
cells. Either aspirin or WY14643 was added at day 6 of
differentiate MK culture for 4 days and MKs were collected
during the terminal days of differentiation to evaluate P2Y1
mRNA expression. The results demonstrated that in mature
MKs both aspirin and WY14643 treatments increase P2Y1
mRNA expression (1.4- and 1.6-fold increases, respectively)
compared with mock culture (►Fig. 2).
P2Y1 Expression in Platelets Obtained from Healthy
Volunteers Treated with Aspirin
To investigate whether aspirin can regulate P2Y1 expression
even after in vivo administration, we explored platelets P2Y1
mRNA expression in platelets obtained from HVs (N ¼ 10)
collected after 1 day, after 3 weeks, after 5 weeks and after
8 weeks of aspirin treatment. Platelet P2Y1 expression levels
showed no increase after 1 day (T1) and after 3 weeks of
treatment (T3). A trend toward an increase was observed
after 5 weeks of treatment (T5), and became statistically
significant (1.4-fold increase) after 8 weeks of treatment
(T8; ►Fig. 3). These data demonstrate that aspirin, even at
low dose (100 mg daily), can induce P2Y1 expression.
Analysis of P2Y1 Expression in Patients on Chronic
Aspirin Treatment
To study P2Y1 platelet expression in patients on chronic
aspirin treatment, we analysed P2Y1 expression in three
different populations: HVs, patients on aspirin treatment
for less than 1 month (ASA < 1 month) and patients on
aspirin therapy for at least 2 months (ASA > 2 months).
Demographic and clinical characteristics, reported
in ►Table 1, show that the two aspirin treated populations
are homogeneous as for gender, age, medication treatment
and cardiovascular risk factors. Compared with HVs, there
was a non-statistically significant increase in P2Y1 expres-
sion levels in patients with ASA < 1 month (►Fig. 4). P2Y1
expression levels were significantly increased in platelets
obtained frompatientswith ASA > 2months comparedwith
both HVs and patients with ASA < 1 month (►Fig. 4).
Platelet Function in Patients with High Levels of P2Y1
Expression
To associate P2Y1 up-regulation and platelet reactivity fol-
lowing ADP stimuli, we studied ADP-induced platelet aggre-
gation in patientswith ASA < 1 month andASA > 2months.
Patients with ASA > 2 months had significantly higher
ADP (2 μM) induced platelet aggregation compared with
those with ASA < 1 month (►Fig. 5).
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Fig. 1 Aspirin stimulates endogenous P2Y1 mRNA and protein expression via a PPARα-dependent mechanism in DAMI cells. (A) Q-RT-PCR
analysis of endogenous P2Y1 expression after 48 and 96 hours (h) of treatment with either 10, 50 or 100 μM aspirin (ASA) and/or 1 μM PPARα
agonist WY14643 (WY). (B) Representative Western blot of endogenous P2Y1 expression for the three experiments performed after 48 hours of
treatment with either 50 μM aspirin (ASA) or 1μM PPARα agonist WY14643 (WY). (C) Densitometric analysis is reported as mean  SD of
increasing fold, compared with control. (D) Control non-specific siRNA (CTR-si) and PPARα specific siRNA (PPAR-si) transfected DAMI cells were
treated for 48 h with either 50 μM aspirin (ASA) or 1 μM PPARα agonist WY14643 (WY). Q-RT-PCR analysis of endogenous P2Y1 expression. Data
were normalized with ACTIN expression and reported as mean  SD of three experiments; statistical differences were evaluated by Student’s
t-test for paired data. NS, not significant; Q-RT-PCR, quantitative real-time polymerase chain reaction.
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Fig. 2 Aspirin stimulates endogenous P2Y1 expression inmegakaryocytes.
Q-RT-PCR analysis of endogenous P2Y1 expression in MKs, derived from
HPCs grown either in mock culture (Ctr) or in the presence of either 50 μM
aspirin (ASA) or 1μMPPARα agonistWY14643 (WY). Data were normalized
with ACTIN expression and reported as mean  SD of three experiments;
statistical differences were evaluated by Student’s t-test for paired data.
Q-RT-PCR, quantitative real-time polymerase chain reaction.
Fig. 3 P2Y1 expression in healthy volunteer (HV) platelets after
aspirin treatment. Q-RT-PCR analysis of P2Y1 mRNA expression levels
in platelets obtained from HVs after 1 day (T1), 3 (T3), 5 (T5) and 8
(T8) weeks of aspirin treatment (100 mg daily). Data were normalized
with ACTIN expression and reported as mean  SD of individual fold
increase after 3, 5 and 8 weeks of treatment of 10 different platelet
samples obtained from HVs; statistical differences were evaluated by
one-way ANOVA test and Bonferroni post-hoc test. NS, not significant;
Q-RT-PCR, quantitative real-time polymerase chain reaction.
Fig. 4 P2Y1mRNA expression in patients under chronic aspirin treatment.
Q-RT-PCR analysis of P2Y1mRNA level expression in platelets obtained from
healthy volunteers (HVs; N ¼ 70), patients under chronic treatment that
began either less than 1 month (ASA < 1 month; N ¼ 40) or more than
2 months (ASA > 2 months; N ¼ 70). Data were normalized with ACTIN
expression. Data are reported as mean  SD; statistical differences were
evaluated by one-way ANOVA test and Bonferroni post-hoc test. NS, not
significant; Q-RT-PCR, quantitative real-time polymerase chain reaction.
Fig. 5 ADP-induced platelet aggregation. Box plot of platelet
aggregation induced by ADP (2 μM). Platelet aggregation is reported
as percentage measured at 4 minutes (%PA) after ADP addition in
patients with ASA > 2 months and ASA < 1 month. Statistical dif-
ference, for data not normally distributed, was evaluated by Wilcoxon
test.
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The increase in aggregation in patients with ASA > 2
months (median: 23%, min: 6%, max: 50%) compared with
those with ASA < 1 month (median: 19%, min: 0%, max:
38%) is also evident in ADP (0.8 μM)-induced platelet pri-
mary aggregation (p ¼ 0.04).
Discussion
In this investigation we demonstrated the effect of aspirin
treatment onMK gene expression leading to up-regulation of
the P2Y1 receptor in human platelets. The modulation of
P2Y1 mRNA and protein expression was shown both in vitro
and in vivo. In particular, DAMI megakaryoblastic cell line
and human culturedMKs showed P2Y1 up-regulation after in
vitro aspirin treatment. Such overexpression was evident
also in platelets obtained from both in vivo aspirin-treated
HVs and in patients on chronic aspirin treatment.
The ability of aspirin to enhance P2Y1 expression attributed
to thenuclear receptorPPARα activation is supportedbysiRNA
experiments, as no P2Y1 up-regulation was observed after
aspirin or WY14643 treatment in PPARα siRNA-transfected
DAMI cells. The relationship between PPARα activation and
drug-dependent platelet P2Y1 up-regulation is in linewith the
data reported forMRP4 expression.11 Therefore, our investiga-
tionstrongly supports theabilityofaspirin tomodulate theMK
gene expression, through PPARα activation, which is then
transferred to the derived platelets since the treatment of
MKs with aspirin induces an enhancement of P2Y1 expression
during the terminal days of differentiation.
The mechanism responsible for the PPARα up-regulation
by aspirin is a still a matter of debate. In our previous paper
we hypothesized that it is induced by two arachidonic acid
metabolites, LTB4 and 20-HETE, that are PPARα ligands and
their production is insensitive to aspirin action, as non-
steroidal anti-inflammatory drugs (NSAIDs) that activate
PPARα.26 In addition, LTB4 and 20-HETE production is higher
in aspirin-treated cells.30 However, a very recent paper
showed that aspirin can bind to PPARα to stimulate hippo-
campal plasticity and protect memory.31 We cannot exclude
that both mechanisms are involved.
Our studyhypothesiswasconfirmedby invivoexperiments
showing that platelets obtained fromHVshad a slight increase
in P2Y1 expression after 5 weeks of aspirin treatment, which
further increased and became statistically different after
8 weeks of treatment. Similarly, in patients on chronic low-
dose aspirin treatment, a slight P2Y1 expression enhancement
was found in platelets obtained from patients who started
aspirin treatment for less than a month, while in platelets
obtained from patients on aspirin treatment for more than
2months, P2Y1expression levelsweresignificantlyhigher. The
effects of aspirin on P2Y1 expression levels are receptor
specific. In fact, we did not see any changes of P2Y12 expres-
sion levels in our preliminary invitro and invivo data (data not
shown).Ourdataare in linewitha recent paperdemonstrating
that another nuclear receptor (i.e., nuclear factor-κB pathway)
is involved in P2Y12 transcription.32
Moreover, platelets obtained from patients on chronic
aspirin treatment for >2 months had higher ADP-induced
platelet reactivity compared with patients on aspirin treat-
ment for <1 month.
These results are in accordance with those found by
others,33 in which it was demonstrated that in platelets
from transgenic mice with enhancement of P2Y1 receptor
density, higher primary platelet aggregation was found.
These results support the hypothesis that platelets with
high P2Y1 levels aremore reactive to ADP, even if a limitation
of this work is that the comparison is made between two
different cohorts of patients on aspirin treatment (and not
the same cohort after 1 and 2 months on aspirin), with
numerous (potential and unknown) confounding variables.
Prior investigations have shown a reduced aspirin effect
on ADP-induced platelet aggregation over time. In a multi-
ple-dose study, platelet aggregation was reduced after
1 week of aspirin administration (20 mg daily), while after
7 to 8 weeks (1,300–2,600 mg daily, respectively), platelet
aggregation returned to baseline values despite inhibition of
thromboxanebiosynthesis.34 In addition, inHVs treatedwith
aspirin (100mg/day) for 8weeks,maximal inhibition of ADP-
induced platelet aggregation was reached after 3 weeks and
displayed a time-dependent recovery, with T-max values at 7
to 8 weeks comparable to those at baseline.18 We also
demonstrated a progressive reduction of inhibition of
ADP-induced platelet aggregation following aspirin ther-
apy.35 Overall, our study findings lead to suggest the pre-
sence of functional recovery of platelet reactivity, which can
be attributed to aspirin-dependent P2Y1 overexpression. We
recognize that a limitation of this work was not to add an
ADP-receptor blocking substance in the in vivo experiments
to study platelet function in patients with high levels of P2Y1
expression. Indeed, future studies evaluating the effect of a
purinergic receptor antagonist would provide further
insights into our study hypothesis.
Drugs can trigger modifications in gene expression that
favour their elimination in eukaryotic cells.36We also demon-
strated that cell exposure to low non-toxic aspirin dosage can
induce an alteration of gene expression that may lead to an
overexpression of the efflux transporter protein increasing
cellular detoxification of aspirin.28 The current investigation
supports an adaptive mechanism, in the genomic and protein
signature of platelets, by which chronic aspirin treatment can
cause a transitory modulation of some genes, to preserve
platelet-dependent haemostatic function. The capability of
aspirin to induce genomic response associated with both
platelet function and adverse clinical outcomes was also evi-
denced in patients with cardiovascular disease.7 In addition,
Floyd et al showed increased platelet expression of glycopro-
tein-IIIa (GpIIIa) following aspirin treatment.8 It is important to
point out that chronic aspirin treatment can enhance platelet
reactivity, through both MRP4 and P2Y1 overexpression, by
modulating the same Gq biochemical pathway.12 In fact, the
purinergic P2Y1 receptor, which triggers calciummobilization
resulting inplatelet shape change andweak, transient aggrega-
tion in response toADP, exerts its effects viaaGqprotein,which
is the samebiochemical pathwayactivatedby thromboxaneA2
receptor,17,19,20 dependent on aspirin-induced MRP4 overex-
pression. Thus, we can speculate that the phenomenon called
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‘platelet adaptation’ in response to pharmacological inhibition,
proposed by others,15 is not receptor specific, but may involve
several receptors that are linked to the same biochemical
pathway. Since the overexpression of P2Y1 in mice is respon-
sible for a platelet hyper-reactive phenotype33 and sinceMRP4
overexpression is PPARα-dependent,11 as is P2Y1, we can
suggest that PPARα activation produces a hyper-reactive plate-
let phenotype with high levels of both MRP4 and P2Y1.
Conclusion
In conclusion, human MKs have an adaptive response to
aspirin treatment, leading to increased P2Y1 expression and
thus enhanced ADP-induced platelet reactivity. These obser-
vations suggest that platelet P2Y1 expression may represent
a useful biomarker to identify patients with high on-aspirin
platelet reactivity (HAPR) and thus at increased risk for
ischaemic events. Larger sample size studies are warranted
to define the clinical implications of this investigation.
What is known about this Topic?
• Aspirin can lead to inhibition of adenosine dipho-
sphate (ADP)-induced mediated signalling. However,
following an initial reduction in platelet activation
with aspirin treatment, an increase in ADP-induced
platelet activation was observed.
• Platelet purinergic P2Y1 receptor (P2Y1) plays a mod-
ulating role on platelet activation.
What does this paper add?
• Aspirin induces genomic changes in megakaryocytes
leading to P2Y1 up-regulation.
• PPARα is the nuclear receptor involved in up-regula-
tion of P2Y1 receptor signalling.
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